Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dynein axonemal light chain 1 (DNAL1)
- Target
- DNAL1
- Molecular classification
- Other (axonemal dynein light chain; cytoskeletal component)
01
Overview
Dynein axonemal light chain 1 (DNAL1) is an integral component of the outer dynein arms in cilia and flagella, serving as part of the molecular motor machinery responsible for ATP-dependent movement. It binds tightly to the dynein gamma heavy chain and interacts with alpha-tubulin, forming a crucial link required for effective ciliary action. DNAL1 is highly expressed in motile ciliated tissues such as respiratory epithelium and sperm flagella. Mutations in DNAL1 disrupt ciliary movement and cause recessive primary ciliary dyskinesia, while its involvement in HIV-1 replication suggests pleiotropic cellular roles. No drugs are known to directly target DNAL1, and therapeutic modulation is limited by its essential cellular function
- Other names
- C14orf168LC1MGC12435CILD16dynein axonemal light chain 1Dynein axonemal light chain 1DNAL1
02
Mechanism of action
Not applicable; no drugs targeting DNAL1 are known.
03
Biological functions
Ciliary and flagellar motility (ATP-dependent movement of cilia/flagella)Cytoskeletal motor activityalpha-tubulin bindingDynein heavy chain binding
04
Disease associations
Primary ciliary dyskinesia (PCD; mutations in DNAL1 cause PCD)Potential role in HIV-1 replication (dependency factor in viral life cycle)
05
Safety considerations
None specific; targeting DNAL1 could pose theoretical risks given its critical role in ciliary motility and broader cellular functions. Mutation leads to loss of cilia function, underlying PCD pathogenesis
06
Biomarkers
DNAL1 mutation (e.g., p.Asn150Ser) is a genetic biomarker for a subset of primary ciliary dyskinesia
Beyond the preview
Go deeper on Dynein axonemal light chain 1 (DNAL1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dynein axonemal light chain 1 (DNAL1).